Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults

Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)

0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).